Drug Resistance Driven by Cancer Stem Cells and Their Niche
AbstractDrug resistance represents one of the greatest challenges in cancer treatment. Cancer stem cells (CSCs), a subset of cells within the tumor with the potential for self-renewal, differentiation and tumorigenicity, are thought to be the major cause of cancer therapy failure due to their considerable chemo- and radioresistance, resulting in tumor recurrence and eventually metastasis. CSCs are situated in a specialized microenvironment termed the niche, mainly composed of fibroblasts and endothelial, mesenchymal and immune cells, which also play pivotal roles in drug resistance. These neighboring cells promote the molecular signaling pathways required for CSC maintenance and survival and also trigger endogenous drug resistance in CSCs. In addition, tumor niche components such as the extracellular matrix also physically shelter CSCs from therapeutic agents. Interestingly, CSCs contribute directly to the niche in a bilateral feedback loop manner. Here, we review the recent advances in the study of CSCs, the niche and especially their collective contribution to resistance, since increasingly studies suggest that this interaction should be considered as a target for therapeutic strategies. View Full-Text
Share & Cite This Article
Prieto-Vila, M.; Takahashi, R.-U.; Usuba, W.; Kohama, I.; Ochiya, T. Drug Resistance Driven by Cancer Stem Cells and Their Niche. Int. J. Mol. Sci. 2017, 18, 2574.
Prieto-Vila M, Takahashi R-U, Usuba W, Kohama I, Ochiya T. Drug Resistance Driven by Cancer Stem Cells and Their Niche. International Journal of Molecular Sciences. 2017; 18(12):2574.Chicago/Turabian Style
Prieto-Vila, Marta; Takahashi, Ryou-u; Usuba, Wataru; Kohama, Isaku; Ochiya, Takahiro. 2017. "Drug Resistance Driven by Cancer Stem Cells and Their Niche." Int. J. Mol. Sci. 18, no. 12: 2574.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.